RION Launches INTENT Biologics to Develop Late-Stage Clinical Exosome-Based Therapies in Inflammation & Immunology; Appoints Biopharma Veteran Suneet Varma as CEO

(RION) ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP™) biologic platform in I&I and will advance PE